Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morton Coleman

Showing results (31-40 of 118) with videos related to

Pageof 12
Sort By:
Leukemia & Lymphoma|February 14, 2015
Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphomaJonathan Reiss, Brian Link, Jia Ruan, et al.
Cancer|March 29, 2002
Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphomaLale Kostakoglu, John P Leonard, Ichiei Kuji, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 7, 2002
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's diseaseLale Kostakoglu, Morton Coleman, John P Leonard, et al.
Oncotarget|December 31, 2015
Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinibAilin Guo, Pin Lu, Natalie Galanina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II studyBrian K Link, Peter Martin, Mark S Kaminski, et al.
Leukemia & Lymphoma|April 11, 2003
BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemiaMorton Coleman, John Leonard, Larry Lyons, et al.
British Journal of Haematology|June 25, 2014
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cellsJiao Ma, Pin Lu, Ailin Guo, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 31, 2013
Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative resultsJia Ruan, Stephanie A Gregory, Paul Christos, et al.
Seminars in Hematology|April 3, 2008
Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphomaPeter Martin, Richard R Furman, Jia Ruan, et al.
Leukemia & Lymphoma|February 26, 2008
Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphomaMorton Coleman, Peter Martin, Jia Ruan, et al.
Pageof 12

Showing results (31-40 of 118) with videos related to

Sort By:
Pageof 12
Leukemia & Lymphoma|February 14, 2015
Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphomaJonathan Reiss, Brian Link, Jia Ruan, et al.
Cancer|March 29, 2002
Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphomaLale Kostakoglu, John P Leonard, Ichiei Kuji, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 7, 2002
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's diseaseLale Kostakoglu, Morton Coleman, John P Leonard, et al.
Oncotarget|December 31, 2015
Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinibAilin Guo, Pin Lu, Natalie Galanina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II studyBrian K Link, Peter Martin, Mark S Kaminski, et al.
Leukemia & Lymphoma|April 11, 2003
BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemiaMorton Coleman, John Leonard, Larry Lyons, et al.
British Journal of Haematology|June 25, 2014
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cellsJiao Ma, Pin Lu, Ailin Guo, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 31, 2013
Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative resultsJia Ruan, Stephanie A Gregory, Paul Christos, et al.
Seminars in Hematology|April 3, 2008
Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphomaPeter Martin, Richard R Furman, Jia Ruan, et al.
Leukemia & Lymphoma|February 26, 2008
Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphomaMorton Coleman, Peter Martin, Jia Ruan, et al.
Pageof 12